MPL proto-oncogene, thrombopoietin receptor
Last updated 14 Apr 2023
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The MPL gene provides instructions for making the thrombopoietin receptor protein, which promotes the growth and division (proliferation) of cells. This receptor is especially important for the proliferation of certain blood cells called megakaryocytes, which produce platelets, the cells involved in blood clotting. Research suggests that the thrombopoietin receptor may also play a role in the maintenance of hematopoietic stem cells, which are stem cells located within the bone marrow that have the potential to develop into red blood cells, white blood cells, and platelets.
Video picks for GenesVideo library
Normal function
The MPL gene provides instructions for making the thrombopoietin receptor protein, which promotes the growth and division (proliferation) of cells. This receptor is especially important for the proliferation of certain blood cells called megakaryocytes, which produce platelets, the cells involved in blood clotting. Research suggests that the thrombopoietin receptor may also play a role in the maintenance of hematopoietic stem cells, which are stem cells located within the bone marrow that have the potential to develop into red blood cells, white blood cells, and platelets.
The thrombopoietin receptor is turned on (activated) when a protein called thrombopoietin attaches (binds) to it. The activated thrombopoietin receptor stimulates a signaling pathway called the JAK/STAT pathway, which transmits chemical signals from outside the cell to the cell's nucleus and is important for controlling the production of blood cells.
Conditions referring to this gene or chromosome
Other names
C-MPL
CD110
MPLV
myeloproliferative leukemia protein
myeloproliferative leukemia virus oncogene
proto-oncogene c-Mpl
thrombopoietin receptor
thrombopoietin receptor precursor
TPO-R
TPOR
TPOR_HUMAN
Patient picks for Genes

Treatment and medication
Proton pump inhibitors
Proton pump inhibitors reduce the amount of acid made by the stomach. They are commonly used to treat acid reflux and ulcers of the stomach and part of the gut called the duodenum. Most people who take a proton pump inhibitor do not develop any side-effects.
by Dr Philippa Vincent, MRCGP

Medicine
Valsartan - an angiotensin receptor blocker
You can take valsartan either before or after a meal. Any side-effects are usually mild. The most common side-effect is dizziness. Some painkillers may interfere with valsartan and increase the risk of side-effects, so ask a pharmacist for advice before you buy any medicines.
by Michael Stewart, MRPharmS

Medicine
Eprosartan - an angiotensin receptor blocker
The usual dose is one 600 mg tablet daily. Side-effects are usually mild. They include headache, feeling dizzy and mild stomach upset. Keep your regular appointments with your doctor to have your blood pressure measured. Some painkillers interfere with eprosartan. Ask your pharmacist for advice before you buy any medicines 'over the counter'.
by Michael Stewart, MRPharmS

Medicine
Irbesartan - an angiotensin receptor blocker
Take irbesartan once each day. You can take the tablets before or after meals. Side-effects are usually mild. They include feeling dizzy and mild stomach upset. Keep your regular appointments with your doctor to have your blood pressure measured. Some painkillers interfere with irbesartan, so ask a pharmacist for advice before you buy any medicines.
by Michael Stewart, MRPharmS

Medicine
Candesartan - an angiotensin receptor blocker
Take candesartan once each day. You can take the tablets either before or after a meal. Any side-effects are usually mild. They include headache and feeling dizzy. Some painkillers may interfere with candesartan and increase the risk of side-effects, so ask a pharmacist for advice before you buy any medicines.
by Michael Stewart, MRPharmS

Medicine
Olmesartan - an angiotensin receptor blocker
Take olmesartan once each day. You can take your doses either before or after a meal. Keep your regular appointments with your doctor to have your blood pressure measured. Some painkillers can interfere with olmesartan and increase the risk of side-effects, so ask a pharmacist for advice before you buy any medicines 'over the counter'.
by Michael Stewart, MRPharmS
Related patient information and medicines

Patient information leaflet
Myelofibrosis
Myelofibrosis is a serious bone marrow disorder that disrupts your body's normal production of blood cells. This leads to reduced levels of: Red blood cells (erythrocytes). This causes anaemia Anaemia. Already having another blood disorder, such as essential thrombocythaemia or polycythaemia rubra vera. Having a gene mutation such as JAK2, CALR,.

Patient information leaflet
Immune thrombocytopenic purpura
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder. In ... Thrombocytopenic , or thrombocytopenia, means not having enough platelets. The National Institute for Health and Care Excellence (NICE) has looked at the evidence for this medicine and advised that it can be used when other medicines have been tried. Specifically, these other.

Patient information leaflet
Coronary artery bypass graft
C oronary artery bypass grafting (CABG) is a type of heart surgery to treat coronary artery disease. The standard surgery requires open heart surgery and stopping of the heart temporarily. Coronary artery bypass grafting, called CABG for ... Ventricular arrhythmias Abnormal heart rhythms - abnormal heart rhythms which can sometimes be serious..

Patient information leaflet
Familial hypercholesterolaemia
Hypercholesterolaemia means cholesterol levels in your blood are too high. Too much cholesterol in your blood causes cholester... What genes are involved in familial hypercholesterolaemia (FH). Dr Krishna Vakharia , 13th September 2024 The National Institute for Health and Care Excellence (NICE) is recommending evinacumab alongside diet and other.

Patient information leaflet
Mastocytosis and mast cell disorders
If the condition is severe, surgery to remove the spleen (splenectomy), medicines that have an effect on the immune system (such as interferon), bone marrow transplant or... Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute for Health and Care Excellence (NICE) has brought out new.

Patient information leaflet
Breast cancer
What is breast cancer? | Patient Explainers Breast cancer is the most common cancer in women. ...) Follow Patient: Website: [https://patient.info/](https://patient.info/) Facebook: [https://www.facebook.com/patient](https://www.facebook.com/patient) Twitter: [https://twitter.com/patient](https://twitter.com/patient) Pinterest:.
Further reading and references
- MPL proto-oncogene, thrombopoietin receptor; MedlinePlus, National Library of Medicine.
- Chaligne R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P, Kiladjian JJ, Socie G, Bordessoule D, Le Bousse-Kerdiles MC, Vainchenker W, Giraudier S. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008 Aug;22(8):1557-66. doi: 10.1038/leu.2008.137. Epub 2008 Jun 5.
- Ding J, Komatsu H, Iida S, Yano H, Kusumoto S, Inagaki A, Mori F, Ri M, Ito A, Wakita A, Ishida T, Nitta M, Ueda R. The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. Blood. 2009 Oct 8;114(15):3325-8. doi: 10.1182/blood-2008-04-149047. Epub 2009 May 29.
- Germeshausen M, Ballmaier M, Welte K. MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. Hum Mutat. 2006 Mar;27(3):296. doi: 10.1002/humu.9415.
- Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006 Jul;3(7):e270. doi: 10.1371/journal.pmed.0030270.
- Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010 Jun;24(6):1128-38. doi: 10.1038/leu.2010.69. Epub 2010 Apr 29.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

